Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Summary of Significant Segment Expenses

Significant segment expenses are presented below.


		Three Months Ended March 31,
		2026				2025
		(in thousands)
Clinical, Preclinical, and R&D Operations (1)		$	(19,367	)		$	(16,386	)
Chemistry, Manufacturing, and Controls (1)			(8,594	)			(6,957	)
General and Administrative (1)			(6,906	)			(5,692	)
Other Segment Items (2)			1,182				1,552
Net loss		$	(33,685	)		$	(27,483	)

(1) Includes depreciation expense directly allocated to respective activities.

(2) Other segment items primarily include interest and accretion income, realized gains and losses, and income taxes.